Patent intelligence · EP
EP 4681704
NEUE FORMULIERUNGEN VON PITOLISANT
NEUE FORMULIERUNGEN VON PITOLISANT
Patent details — EP 4681704
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Jan 21, 2026
- Expiration
- Jan 16, 2046
- Applicant
- BIOPROJET PHARMA [FR]
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 4453 A I, A61K/314453
Quick answer
EP 4681704 (NEUE FORMULIERUNGEN VON PITOLISANT) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Jan 21, 2026. Expires Jan 16, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOPROJET PHARMA [FR]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 9/ 28 A I, A61K 31/ 4453 A I, A61K/314453, A61K/92009, A61K/92846
More from BIOPROJET PHARMA [FR]
Related pharmaceutical patents in our USPTO index.
-
EP 4732903
COKRISTALLE VON PITOLISTANTHYDROCHLORID
granted -
US 2025120959
NEW FORMULATIONS OF PITOLISANT AND METHODS OF USE
granted -
US 2024327366
POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE
granted -
EP 3906927
VERWENDUNG VON DOPAMIN-D3-TEILAGONISTEN ZUR BEHANDLUNG VON STÖRUNGEN DES ZENTRALEN NERVENSYSTEMS
granted -
US 2020024256
TETRAHYDRATE OF H3 LIGAND, ITS PROCESS OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
granted -
EP 3378477
NEUE THERAPEUTISCHE VERWENDUNGEN VON H3-LIGANDEN
granted -
EP 2511275
Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten
granted
Frequently asked questions
What is US patent 4681704?
EP 4681704 (NEUE FORMULIERUNGEN VON PITOLISANT) is held by BIOPROJET PHARMA [FR]. Status: granted. Granted Jan 21, 2026. Expires Jan 16, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4681704?
BIOPROJET PHARMA [FR] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does EP 4681704 expire?
Our index shows an expiration date of Jan 16, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.